[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617544":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":35,"collaborators":11,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":11,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":11},{"fullName":5,"class":6},"Holy Family Hospital, Pakistan","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bleomycin sclerotherapy","ACTIVE_COMPARATOR",null,[13],"Drug: Bleomycin",{"label":15,"type":16,"description":11,"interventionNames":17},"Doxycycline sclerotherapy","EXPERIMENTAL",[18],"Drug: doxycycline (tetracycline)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Bleomycin","Injection sclerotherapy using bleomycin administered according to standard hospital protocol. The number of sessions and dosage are determined based on lesion size and patient response. Safety and adverse events are monitored by the principal investigator and treating physicians.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"doxycycline (tetracycline)","Injection sclerotherapy using doxycycline administered according to hospital protocol. The number of sessions and dosage are determined based on lesion size and patient response. Safety and adverse events are monitored by the principal investigator and treating physicians.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Basharat Hussain","CONTACT","03115130677","basharatbasharathussain@gmail.com",{"type":36,"investigatorFullName":31,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Principal Investigator","100617544","phase-2-injection-sclerotherapy-with-bleomycin-vs-doxycycline-in-patients-with-lymphatic-malformations-100617544",false,"NCT07320001","Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations","Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations:A Randomized Controlled Trial","Inclusion Criteria:\n\nAge 0-12 years Radiological diagnosis of macrocytic\u002Fmixed lymphatic malformations. No prior sclerotherapy\u002Fsurgical treatment. Informed consent from guardians\n\n\\-\n\nExclusion Criteria:\n\n* microcytic lymphatic malformations Allergies to bleomycin\u002FDoxycycline. Significant co morbidities Active infection at lesion site.","ALL","0 Years","12 Years",{"count":49,"type":50},92,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","This is a randomized clinical trial comparing the safety and effectiveness of injection sclerotherapy using bleomycin versus doxycycline in children under 12 years with lymphatic malformations. The study will assess reduction in lesion size, clinical improvement, and treatment-related complications over six months.",[56],"Lymphatic Abnormality","NOT_YET_RECRUITING","2025-12-20",{"date":60,"type":61},"2026-01-06","ACTUAL",{"date":63,"type":50},"2026-01-26",{"date":65,"type":50},"2026-09-26",{"name":31,"class":6}]